CN113950327A - 口服胶囊剂及其制备方法 - Google Patents

口服胶囊剂及其制备方法 Download PDF

Info

Publication number
CN113950327A
CN113950327A CN202080043268.7A CN202080043268A CN113950327A CN 113950327 A CN113950327 A CN 113950327A CN 202080043268 A CN202080043268 A CN 202080043268A CN 113950327 A CN113950327 A CN 113950327A
Authority
CN
China
Prior art keywords
capsule
oral capsule
oral
mixing
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080043268.7A
Other languages
English (en)
Chinese (zh)
Inventor
王亦平
郭远静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beone Pharmaceutical Suzhou Co Ltd
Original Assignee
Baiji Shenzhou Switzerland Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baiji Shenzhou Switzerland Co ltd filed Critical Baiji Shenzhou Switzerland Co ltd
Publication of CN113950327A publication Critical patent/CN113950327A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080043268.7A 2019-06-10 2020-06-10 口服胶囊剂及其制备方法 Pending CN113950327A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019090543 2019-06-10
CNPCT/CN2019/090543 2019-06-10
PCT/CN2020/095353 WO2020249002A1 (zh) 2019-06-10 2020-06-10 口服胶囊剂及其制备方法

Publications (1)

Publication Number Publication Date
CN113950327A true CN113950327A (zh) 2022-01-18

Family

ID=73780902

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080043268.7A Pending CN113950327A (zh) 2019-06-10 2020-06-10 口服胶囊剂及其制备方法

Country Status (6)

Country Link
US (2) US20220241285A1 (https=)
EP (1) EP3981400A4 (https=)
JP (2) JP2022538215A (https=)
CN (1) CN113950327A (https=)
TW (1) TW202112369A (https=)
WO (1) WO2020249002A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119818691A (zh) * 2025-03-18 2025-04-15 宁波美诺华天康药业有限公司 一种含有伊布替尼的药物组合物及其制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
WO2018033853A2 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
US20220249491A1 (en) 2019-06-10 2022-08-11 Beigene Switzerland Gmbh Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
CN115212115A (zh) * 2021-09-27 2022-10-21 百济神州(苏州)生物科技有限公司 泽布替尼的鼻饲给药
CN119699478B (zh) * 2024-12-24 2025-12-12 衡睿(广东)生物科技有限公司 一种高油脂含量的胶囊制剂及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014173289A1 (en) * 2013-04-25 2014-10-30 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
WO2018033853A2 (en) * 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2019183226A1 (en) * 2018-03-21 2019-09-26 Mei Pharma, Inc. Combination therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
US10688050B1 (en) * 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014173289A1 (en) * 2013-04-25 2014-10-30 Beigene, Ltd. Fused heterocyclic compounds as protein kinase inhibitors
WO2018033853A2 (en) * 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2019183226A1 (en) * 2018-03-21 2019-09-26 Mei Pharma, Inc. Combination therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
20170702: "BEIGENE Efficacy and Safety of BGB-3111 in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", 《HTTPS://CLINICALTRIALS.GOV/CT2/SHOW/NCT03206918》 *
TAM C.S.等: "A Head-to-head Phase III Study Comparing Zanubrutinib Versus Ibrutinib in Patients with Waldenstrom macroglobulinemia", 《FUTURE ONCOLOGY》 *
百济神州（北京）生物科技有限公司: "评估BTK抑制剂BGB-3111在中国B淋巴细胞肿瘤患者的安全性、耐受性以及药代/药效动力学特征的I期临床研究", 《HTTP://WWW.CHINADRUGTRIALS.ORG.CN》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119818691A (zh) * 2025-03-18 2025-04-15 宁波美诺华天康药业有限公司 一种含有伊布替尼的药物组合物及其制备方法

Also Published As

Publication number Publication date
TW202112369A (zh) 2021-04-01
JP2025123534A (ja) 2025-08-22
WO2020249002A1 (zh) 2020-12-17
EP3981400A4 (en) 2023-07-12
US20220241285A1 (en) 2022-08-04
US20230149411A1 (en) 2023-05-18
JP2022538215A (ja) 2022-09-01
EP3981400A1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
CN113950327A (zh) 口服胶囊剂及其制备方法
US12233069B2 (en) Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor
CN116157391A (zh) 包含egfr抑制剂的药物组合物及其制备方法
CN106420743A (zh) C‑met调节剂药物组合物
CN102988296A (zh) 塞来昔布固体分散体及其制备方法
CN102266307A (zh) 一种缬沙坦胶囊及其制备方法
CN112472675A (zh) 司来帕格片剂及其制备方法
CN111514142A (zh) 含硝羟喹啉前药的药物组合物及其制备方法和应用
TWI794214B (zh) 包含5-氯-n4-[2-(二甲基磷醯基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺之醫藥調配物
JP2019142927A (ja) 医薬剤形
CN109875972B (zh) 一种奥美沙坦酯氨氯地平药物组合物
CN114053235B (zh) 茶碱缓释片及其制备方法
CN110960501B (zh) 一种诺氟沙星胶囊及其制备方法
CN113827602B (zh) 醋酸阿比特龙药物组合物、制剂、其制备方法及其应用
KR20160038837A (ko) 오셀타미비어 함유 과립, 그 과립을 포함하는 캡슐제, 및 이들의 제조방법
CN111249241B (zh) 一种含有难溶性噻吩并吡啶组合物的固体制剂及制备方法
CN118766862A (zh) 一种贝派度酸速释片及其制备方法
CN109700773B (zh) 一种替格瑞洛制剂组合物及其制备方法
CN108014343A (zh) 一种治疗乳腺癌的药物组合物及其制备方法
CN112057427B (zh) 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
CN112057432A (zh) 口服胶囊剂及其制备方法
CN108938586A (zh) 一种含有喹啉衍生物或其盐的药物组合物的制备方法
HK40066903A (en) Oral capsule and preparation method therefor
CN111714444B (zh) 一种醋酸乌利司他口服固体制剂及其制备方法
CN117919186A (zh) 一种甲磺酸沙芬酰胺片及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20251027

Address after: 215002 Jiangsu Province Suzhou City China (Shanghai) Pilot Free Trade Zone Suzhou Area Suzhou Industrial Park Jinhai Road 29.NO

Applicant after: Baiji Shenzhou (Suzhou) Biotechnology Co.,Ltd.

Country or region after: China

Address before: 27 ashengraben, 4051 Basel, Switzerland

Applicant before: Baiji Shenzhou Switzerland Co.,Ltd.

Country or region before: Switzerland

TA01 Transfer of patent application right